Keyword: Versant Ventures
The series B tees the allosteric oncogenic mutation specialist up to move two or three candidates into the clinic.
Versant Ventures unveiled a $600 million global biotech fund, its seventh, and a $100 million companion fund that will focus on startups in Canada.
Akero will push a nonalcoholic steatohepatitis treatment licensed from Amgen through phase 2, and expand its pipeline.
Versant Ventures is unveiling Black Diamond Therapeutics, a biotech developing cancer treatments for an “undrugged and unexplored” group of oncogenes.
Genentech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount.
Ophthotech has signed novel drug and gene therapy deals to bulk up its pipeline following the demise of its wet AMD candidate last year.
Gotham Therapeutics has raised $54 million to advance small-molecule inhibitors of mRNA-modifying proteins as far as clinical proof of concept.
Coda Biotherapeutics' goal is to create a gene therapy that can be switched on and off, and dialed up and down.
Akero Therapeutics raised $65 million to advance its lead program, a FGF21 analog, for the treatment of NASH.
The cash equips Lava to advance bispecific engagers of γδ T cells, a small subgroup of lymphocytes involved in natural and induced immunity to cancer.